TY - JOUR
T1 - Current progress in antivascular tumor therapy
AU - Ho, Yi Ju
AU - Wang, Tzu Chia
AU - Fan, Ching Hsiang
AU - Yeh, Chih Kuang
N1 - Funding Information:
The authors gratefully acknowledge the support of the Ministry of Science and Technology, Taiwan , under Grant Nos 105-2221-E-007-055 and 105-2119-M-182-001 , National Tsing Hua University (Hsinchu, Taiwan) under Grant No. 106N522CE1 , and Chang Gung Memorial Hospital (Linkou, Taiwan) under Grant No. CIRPD2E0051 . Yi-Ju Ho obtained her PhD at the Department of Biomedical Engineering and Environmental Sciences in the National Tsing Hua University, Hsinchu, Taiwan, in 2017. She joined the laboratory of Prof. Chih-Kuang Yeh at the National Tsing Hua University for postdoctoral training. Her research interests focus on the theranostic applications of ultrasound with acoustic phase change droplet for cellular bioeffect, antivascular therapy and tumor microenvironment regulation. Ching-Hsiang Fan received his PhD in the Department of Biomedical Engineering and Environmental Sciences from National Tsing Hua University, Hsinchu, Taiwan. He is currently a postdoctoral research fellow of National Tsing Hua University, Hsinchu, Taiwan. His current research interests include multifunctional microbubble-based drug delivery, ultrasound with microbubble-induced blood–brain barrier opening for brain drug/gene delivery and ultrasound with microbubble-induced intracellular signal transduction. Chih-Kuang Yeh was born in 1973 in Taiwan. He received his PhD degree in electrical engineering from National Taiwan University, Taipei, Taiwan, in 2004. He joined Professor Katherine Ferrara’s research group in the University of California at Davis as a visiting researcher from 2003 to 2004. In 2005, he joined the Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan. He is now a distinguished professor at National Tsing Hua University. His current research interests include ultrasound theranostics and ultrasound-mediated drug/gene delivery.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/10
Y1 - 2017/10
N2 - The tumor vasculature transports oxygen, nutrients and drugs for crucial roles in tumor therapy. Antivascular therapy directly targets existing tumor vessels to reduce blood perfusion and then inhibit tumor growth. Vascular disrupting agents and ultrasound-stimulated microbubble destruction use chemical toxicity and physical effect, respectively, to damage vascular endothelial cells for antivascular therapy. Moreover, antivascular therapy can break vessel wall barriers and change the tumor microenvironment to compensate for the limitations of conventional chemotherapy or radiotherapy. This review presents current progress and an overview of antivascular therapy, which can inform the development and application in cancer research. This review presents current progress and an overview of antivascular therapy to inform its development and application in cancer research.
AB - The tumor vasculature transports oxygen, nutrients and drugs for crucial roles in tumor therapy. Antivascular therapy directly targets existing tumor vessels to reduce blood perfusion and then inhibit tumor growth. Vascular disrupting agents and ultrasound-stimulated microbubble destruction use chemical toxicity and physical effect, respectively, to damage vascular endothelial cells for antivascular therapy. Moreover, antivascular therapy can break vessel wall barriers and change the tumor microenvironment to compensate for the limitations of conventional chemotherapy or radiotherapy. This review presents current progress and an overview of antivascular therapy, which can inform the development and application in cancer research. This review presents current progress and an overview of antivascular therapy to inform its development and application in cancer research.
UR - http://www.scopus.com/inward/record.url?scp=85021304789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021304789&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2017.06.001
DO - 10.1016/j.drudis.2017.06.001
M3 - Review article
C2 - 28625610
AN - SCOPUS:85021304789
VL - 22
SP - 1503
EP - 1515
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 10
ER -
